On the one hand, Galluzzi provided preclinical evidence supporting the ability of low-dose whole-body RT delivered shortly before infusion of CD19-targeting chimeric antigen receptor (CAR) T cells to extent their efficacy against human CD19+ acute lymphoblastic leukemia cells growing in immunodeficient mice. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.